EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

EXT418, a novel long‐acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice

Haiming L Kerr iD, Kora Krumm, Ian In-Gi Lee, Barbara Anderson, Anthony Christiani, Lena Strait, Beatrice A Breckheimer, Brynn Irwin, Alice Siyi Jiang, Artur Rybachok, Amanda Chen, Lucas Caeiro und 6 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2023-06 · 14 (3) · 1337-1348

DOI: 10.1002/jcsm.13211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 21.03.2023. Verfasst von Haiming L Kerr und 17 weiteren Autor:innen. Beteiligte Einrichtung: Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Cachexia, Carcinoma, Lewis Lung. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, BLRD VA, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ghrelin is a potential therapy for cachexia due to its orexigenic properties and anabolic effects on muscle and fat. However, its clinical use is limited by the short half‐life of active (acylated) ghrelin (~11 min in humans). EXT418 is a novel long‐acting, constitutively active ghrelin analog created by covalently linking it to a vitamin D derivative. Here, we evaluated the effects and mechanisms of action of EXT418 on Lewis lung carcinoma (LLC)‐induced cachexia in mice.

Methods

Male C57BL/6J mice (5‐ to 7‐month‐old) were implanted with 1 × 10 6 heat‐killed (HK) or live LLC cells. When the tumour was palpable, mice were injected with vehicle (T + V) or EXT418 daily (T + 418 Daily, 0.25 mg/kg/day) or every other day (T + 418 EOD, 0.5 mg/kg/EOD) for up to 14 days, whereas HK‐treated mice were given vehicle (HK + V). Subsets of T + 418 Daily or EOD‐treated mice were pair‐fed to the T + V group. Body composition and grip strength were evaluated before tumour implantation and at the end of the experiment. Molecular markers were probed in muscles upon termination.

Results

In tumour‐bearing mice, administration of EXT418 daily or EOD partially prevented weight loss (T + V vs. T + 418 Daily, P = 0.030; and vs. T + 418 EOD, P = 0.020). Similar effects were observed in whole body fat and lean body mass. Grip strength in tumour‐bearing mice was improved by EXT418 daily ( P = 0.010) or EOD ( P = 0.008) administration compared with vehicle‐treated mice. These effects of EXT418 on weight and grip strength were partially independent of food intake. EXT418 daily administration also improved type IIA ( P = 0.015), IIB ( P = 0.037) and IIX ( P = 0.050) fibre cross‐sectional area (CSA) in tibialis anterior (TA) and EXT418 EOD improved CSA of IIB fibres in red gastrocnemius (GAS; P = 0.005). In skeletal muscles, tumour‐induced increases in atrogenes Fbxo32 and Trim63 were ameliorated by EXT418 treatments (TA and GAS/plantaris, PL), which were independent of food intake. EXT418 administration decreased expression of the mitophagy marker Bnip3 (GAS/PL; P ≤ 0.010). Similar effects of EXT418 EOD were observed in p62 (GAS/PL; P = 0.039). In addition, EXT418 treatments ameliorated the tumour‐induced elevation in muscle Il6 transcript levels (TA and GAS/PL), independently of food intake. Il‐6 transcript levels in adipose tissue and circulating IL‐10 were elevated in response to the tumour but these increases were not significant with EXT418 administration. Tumour mass was not altered by EXT418.

Conclusions

EXT418 mitigates LLC‐induced cachexia by attenuating skeletal muscle inflammation, proteolysis, and mitophagy, without affecting tumour mass and partially independent of food intake.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaCarcinoma, Lewis LungAnimalsHumansMaleMiceGhrelinMice, Inbred C57BLWeight Loss

Stichwörter der Autor:innen

CachexiaGhrelinInflammationMitophagyWasting

Substanzen

Ghrelin

Autor:innen und Institutionen

  • Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.
  • Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington School of Medicine, Washington, Seattle, USA.
  • Extend Biosciences, Inc., St. Newton, Massachusetts, USA.
  • Atalanta Therapeutics, Boston, Massachusetts, USA.

ORCID-Profile: Haiming L Kerr, Jose M Garcia

Förderung

  • NHLBI NIH HHS
  • BLRD VA
  • NCI NIH HHS
  • NIDDK NIH HHS
  • NIA NIH HHS
  • U.S. Department of Veterans Affairs
  • Common Fund
  • Congressionally Directed Medical Research Programs

Zitieren

APA

Kerr, H. L., Krumm, K., Lee, I. I., Anderson, B., Christiani, A., Strait, L., Breckheimer, B. A., Irwin, B., Jiang, A. S., Rybachok, A., Chen, A., Caeiro, L., Dacek, E., Hall, D. B., Kostyla, C. H., Hales, L. M., Soliman, T. M., & Garcia, J. M. (2023). EXT418, a novel long‐acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice. Journal of Cachexia, Sarcopenia and Muscle, 14(3), 1337-1348. https://doi.org/10.1002/jcsm.13211

Vancouver

Kerr HL, Krumm K, Lee II, Anderson B, Christiani A, Strait L, et al. EXT418, a novel long‐acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice. Journal of Cachexia, Sarcopenia and Muscle. 2023;14(3):1337-1348. doi:10.1002/jcsm.13211

BibTeX
@article{Kerr2023,
  author = {Kerr, Haiming L and Krumm, Kora and Lee, Ian In-Gi and Anderson, Barbara and Christiani, Anthony and Strait, Lena and Breckheimer, Beatrice A and Irwin, Brynn and Jiang, Alice Siyi and Rybachok, Artur and Chen, Amanda and Caeiro, Lucas and Dacek, Elizabeth and Hall, Daniel B and Kostyla, Caroline H and Hales, Laura M and Soliman, Tarik M and Garcia, Jose M},
  title = {EXT418, a novel long‐acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2023},
  volume = {14},
  number = {3},
  pages = {1337--1348},
  doi = {10.1002/jcsm.13211}
}
Kostenlos starten →